<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01122264</url>
  </required_header>
  <id_info>
    <org_study_id>13085</org_study_id>
    <secondary_id>H6D-EW-LVIJ</secondary_id>
    <nct_id>NCT01122264</nct_id>
  </id_info>
  <brief_title>A Study in Patients With Erectile Dysfunction</brief_title>
  <official_title>Impact of Tadalafil (LY450190) Once a Day or Tadalafil on Demand Compared to Sildenafil Citrate on Demand on Treatment Discontinuation in Patients With Erectile Dysfunction Who Are na√Øve to PDE5 Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if treatment in erectile dysfunction with a
      long-acting drug (Tadalafil) taken once a day or taken as needed results in a longer
      treatment adherence and better long term outcomes (over 24 weeks), compared with a
      short-acting drug (Sildenafil Citrate) taken as needed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Discontinuation of Randomized Treatment</measure>
    <time_frame>Baseline up to 334 days</time_frame>
    <description>Time to discontinuation of randomized treatment was defined as the number of days from randomization until the day the participant discontinued the randomized treatment. Discontinuation of randomized treatment was defined as switching between the 3 study treatments (tadalafil on demand, tadalafil once a day, or sildenafil citrate on demand) or discontinuing from all treatments. A change of dose within the same treatment was not considered switching of treatment. This outcome measure was estimated using the Kaplan-Meier product-limit method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Erectile Function (EF) Domain</measure>
    <time_frame>Baseline, 4, 8, 16, and 24 weeks</time_frame>
    <description>Self-reported EF score over past 4 weeks. Items 1-5 scores range from 0 (no sexual activity) to 5 (high EF). Item 15 score ranges from 1 (very low confidence to get/keep erection) to 5 (very high confidence). Total scores range from 1 to 30; lower scores denote greater erectile dysfunction severity. Least Squares Mean changes from baseline to endpoint for each visit from repeated measures analysis included terms for baseline score, treatment group, country, baseline*treatment (if p&lt;0.10), visit, and visit*treatment. Correlation matrix for repeated observations assumed to be unstructured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Orgasmic Function Domain</measure>
    <time_frame>Baseline, 4, 8, 16, and 24 weeks</time_frame>
    <description>Self-reported orgasmic function on the IIEF over past 4 weeks and consists of 2 questions (items 9 and 10). Each question is rated on a scale from 0 (no sexual stimulation) to 5 (almost always/always). Total scores range from 0 to 10; lower scores represent lower orgasmic function. Least Squares Mean changes from baseline to endpoint for each visit were from a repeated measures analysis and included terms for baseline score, treatment group, country, baseline*treatment (if p&lt;0.10), visit, and visit*treatment. The correlation matrix for the repeated observations was assumed to be unstructured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Sexual Desire Domain</measure>
    <time_frame>Baseline, 4, 8, 16, and 24 weeks</time_frame>
    <description>Self-reported sexual desire on IIEF over past 4 weeks; comprises 2 questions (items 11 and 12). Each question rated on a scale from 1 (almost never or low/no sexual desire) to 5 (almost always or very high sexual desire). Total scores range: 2 to 10; lower numerical scores denote lower sexual desire. Least Squares Mean changes from baseline to endpoint for each visit from repeated measures analysis and included terms for baseline score, treatment group, country, baseline*treatment (if p&lt;0.10), visit, and visit*treatment. Correlation matrix for repeated observations assumed to be unstructured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 4, 8, 16 and 24 Weeks of the Sexual Encounter Profile (SEP)</measure>
    <time_frame>Baseline, 4, 8, 16, and 24 weeks</time_frame>
    <description>Participant-assessed diary. Has 5 questions (Question[Q]1:erection achievement, Q2:successful penetration, Q3:successful intercourse, Q4:satisfied with erection, and Q5:satisfied with sexual experience) for each sexual encounter made over specified period of time. SEP Q1-Q5 scores determined as percentage of 'Yes' responses to each of 5 questions out of all sexual attempts recorded during the time period. Least Squares Mean changes from baseline to endpoint for each visit from a repeated measures analysis included terms for baseline score, treatment group, country, visit, and visit*treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assessment Questions (GAQ)</measure>
    <time_frame>24 weeks</time_frame>
    <description>The GAQ consists of 2 Yes/No/No Response (No Respo) questions. GAQ Question (Q)1: Has the treatment you have been taking during this study improved your erections? GAQ Q2: Has the treatment improved your ability to engage in sexual activity?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Treatment Switches</measure>
    <time_frame>Baseline through 24 weeks</time_frame>
    <description>The number of times participants switched erectile dysfunction medication within the 3 treatments being studied (tadalafil on demand, tadalafil once a day, or sildenafil citrate on demand).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patterns of Erectile Dysfunction Treatment Change</measure>
    <time_frame>Baseline through 24 weeks</time_frame>
    <description>Results are reported as the number of participants per sequence of study medications (tadalafil on demand, tadalafil once a day, or sildenafil citrate on demand) that were taken as a result of switching treatments. The Other Treatment Sequence reports the number of participants per sequence of study medications that were taken as a result of switching treatments more than once. The number of participants who did not switch is also reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for Discontinuation of Randomized Erectile Dysfunction Treatment</measure>
    <time_frame>Baseline through 24 weeks</time_frame>
    <description>The reported reasons for a decision to discontinue from initial randomized treatment prior to Week 24 are reported. Discontinuation of randomized treatment was defined as switching between the 3 study treatments (tadalafil on demand, tadalafil once a day, or sildenafil citrate on demand) or discontinuing from all treatments. A change of dose within the same treatment was not considered as switching of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days From the 8-Week Study Visit to the Time the Participant Discontinues From All Phosphodiesterase Type 5 (PDE5) Inhibitor Treatments</measure>
    <time_frame>8 weeks up to 334 days</time_frame>
    <description>The differences in time between the 8-week time point and the discontinuation of all study treatments (that is, discontinuation from the study and not switching to another treatment) are reported by the median (95% confidence interval). Duration was measured as the number of days from Week 8 to the date of the last dose of the study drug. This outcome measure was estimated using the Kaplan-Meier product-limit method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Intercourse Satisfaction Domain</measure>
    <time_frame>Baseline, 4, 8, 16, and 24 weeks</time_frame>
    <description>Self-reported intercourse satisfaction score over past 4 weeks (1 intercourse attempt item, 2 intercourse satisfaction items). Each item range: 0 (no intercourse attempts/no satisfaction) to 5 (more attempts/high satisfaction). Total scores range: 0-15; lower scores=lower intercourse satisfaction. Least Squares Mean changes from baseline to endpoint for each visit from repeated measures analysis and included terms for baseline score, treatment group, country, baseline*treatment (if p&lt;0.10), visit, and visit*treatment. Correlation matrix for repeated observations assumed to be unstructured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Overall Satisfaction Domain</measure>
    <time_frame>Baseline, 4, 8, 16, and 24 weeks</time_frame>
    <description>Self-reported overall satisfaction on the IIEF over past 4 weeks and consists of 2 questions (items 13 and 14), each rated on a scale from 1 (very dissatisfied) to 5 (very satisfied). Total scores range from 2 to 10; lower numerical scores represent lower overall satisfaction. Least Squares Mean changes from baseline to endpoint for each visit were from a repeated measures analysis and included terms for baseline score, treatment group, country, baseline*treatment (if p&lt;0.10), visit, and visit*treatment. The correlation matrix for the repeated observations was assumed to be unstructured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire at 4, 8, 16, and 24 Weeks</measure>
    <time_frame>4, 8, 16, and 24 weeks</time_frame>
    <description>The participant questionnaire consists of 11 questions. Each question is rated on a scale of 0 (extremely low treatment satisfaction) to 4 (extremely high treatment satisfaction). The EDITS summary score was obtained by adding each individual result for all questions, dividing by the number of questions answered (mean satisfaction score), then multiplying by 25, thus obtaining a score range from 0 (extremely low treatment satisfaction) to 100 (extremely high satisfaction). Least Squares Mean changes were adjusted for treatment group, country, visit, and visit*treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 24 Week Endpoint of the Sexual Self-Confidence, Spontaneity, and Time Concerns Domains (23-items) of the Psychological and Interpersonal Relationships Scale (PAIRS)</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
    <description>The PAIRS is a 23-item scale that assesses broader psychological/interpersonal outcomes associated with erectile dysfunction and its treatment. Each question is rated on a Likert scale from 1 (strongly disagree) to 4 (strongly agree). The scale consists of 3 domains: Sexual Self-Confidence (items 1-6), Spontaneity domain (items 7-15), and Time Concerns (items 16-23). The average domain score for each domain was calculated by adding the nonmissing items for the respective domain, then dividing by the number of nonmissing items for the respective domain. Each average domain score ranged from 1 to 4. Higher scores represent the following: greater sexual self-confidence (better outcome); greater spontaneity (better outcome); higher time concerns (worse outcome). The Least Squares Mean changes were adjusted for treatment group, country, baseline IIEF-EF severity, baseline domain score, and baseline domain score*treatment (if p&lt;0.10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 4, 8, 16, and 24 Weeks of the Sexual Relationship Domain of the Self-Esteem and Relationship (SEAR) Questionnaire</measure>
    <time_frame>Baseline, 4, 8, 16, and 24 weeks</time_frame>
    <description>SEAR assesses psychosocial outcomes in men with erectile dysfunction. Sexual Relationship domain consists of 8 items (items 1-8). Items 2-8 are rated on a scale of 1 (Never) to 5 (Always), whereas item 1 is reverse scored (1=Always and 5=Never). The domain score was computed by summing its respective items, then transforming it into a 0 (least favorable) to 100 (most favorable) scale. Transformed score = 100 x [(actual raw score - lowest possible raw score)/possible raw score range]. Least Squares Mean changes adjusted for baseline score, treatment group, country, visit, and visit*treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 4, 8, 16, and 24 Weeks of the Confidence Domain of the Self-Esteem and Relationship (SEAR) Questionnaire</measure>
    <time_frame>Baseline, 4, 8, 16, and 24 weeks</time_frame>
    <description>SEAR assesses psychosocial outcomes in men with erectile dysfunction. Confidence domain measures improvement in confidence; 2 subscales (6 items: Self-Esteem [items 9-12]; Overall Relationship [items 13-14]). Each item range: 1 (Never) to 5 (Always); item 11 reverse scored. Domain score=sum of domain's respective items, then transformed into 0 (least favorable) to 100 (most favorable) scale. Transformed score=100x[(actual raw score-lowest possible raw score)/possible raw score range]. Least Squares Mean change adjusted for baseline score, treatment group, country, visit, and visit*treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 4, 8, 16, and 24 Weeks of the Self Esteem Domain of the Self-Esteem and Relationship (SEAR) Questionnaire</measure>
    <time_frame>Baseline, 4, 8, 16, and 24 weeks</time_frame>
    <description>SEAR assesses psychosocial outcomes in men with erectile dysfunction. The Self-Esteem domain consists of 4 items (items 9-12), each rated on a scale of 1 (Never) to 5 (Always). Item 11 is reverse scored (1=Always and 5=Never). The domain score was computed by summing its respective items, then transforming it into a 0 (least favorable) to 100 (most favorable) scale. The transformed score = 100 x [(actual raw score - lowest possible raw score)/possible raw score range]. Least Squares Mean changes were adjusted for baseline score, treatment group, country, visit, and visit*treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 4, 8, 16, and 24 Weeks of the Overall Relationship Domain of the Self-Esteem and Relationship (SEAR) Questionnaire</measure>
    <time_frame>Baseline, 4, 8, 16, and 24 weeks</time_frame>
    <description>SEAR assesses psychosocial outcomes in men with erectile dysfunction. The Overall Relationship domain consists of 2 items (items 13-14), each rated on a scale of 1 (Never) to 5 (Always). The domain score was computed by summing its respective items, then transforming it into a 0 (least favorable) to 100 (most favorable) scale. The transformed score = 100 x [(actual raw score - lowest possible raw score)/possible raw score range]. Least Squares Mean changes were adjusted for baseline score, treatment group, country, visit, and visit*treatment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">770</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Tadalafil on demand</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 milligrams (mg) or 20 mg on demand</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tadalafil once a day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg or 2.5 mg once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sildenafil Citrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 mg, 100 mg, or 25 mg on demand</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil</intervention_name>
    <description>Administered orally for 24 weeks.</description>
    <arm_group_label>Tadalafil on demand</arm_group_label>
    <arm_group_label>Tadalafil once a day</arm_group_label>
    <other_name>Cialis</other_name>
    <other_name>LY450190</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil Citrate</intervention_name>
    <description>Administered orally for 24 weeks.</description>
    <arm_group_label>Sildenafil Citrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of Erectile Dysfunction (ED) of at least 3 months duration.

          -  Anticipate having the same adult female sexual partner during the study.

          -  Agree not to use any other treatment for ED and to participate in recording responses
             to questionnaires and other instruments used in this study.

        Exclusion Criteria:

          -  Previous or current treatment with tadalafil or any other phosphodiesterase type 5
             (PDE5) inhibitor.

          -  ED caused by other primary sexual disorders, history of radical prostatectomy or other
             pelvic surgery with subsequent failure to achieve any erection, or history of penile
             implant or clinically significant penile deformity.

          -  ED caused by untreated or inadequately treated endocrine disease.

          -  Current treatment with doxazosin, nitrates, cancer chemotherapy, or anti-androgens.

          -  Severe renal or hepatic impairment, history of malignant hypertension.

          -  Presence or history of specific heart conditions.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Carpentras</city>
        <zip>84200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chambery</city>
        <zip>73000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>La Bouexiere</city>
        <zip>35340</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Montpellier</city>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Murs-Erigne</city>
        <zip>49610</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nantes</city>
        <zip>44300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rennes</city>
        <zip>35 700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Giengen</city>
        <zip>89537</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Grevenbroich</city>
        <zip>41515</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Holzminden</city>
        <zip>D-37603</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Koblenz</city>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Leipzig</city>
        <zip>04109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Leverkusen</city>
        <zip>51375</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Luebeck</city>
        <zip>23552</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Marburg</city>
        <zip>35039</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Muehlacker</city>
        <zip>D-75417</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Warburg</city>
        <zip>34414</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Heraklion</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Larissa</city>
        <zip>41221</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Patras</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kutno</city>
        <zip>99-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Legionowo</city>
        <zip>05-120</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lublin</city>
        <zip>20-008</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Warsaw</city>
        <zip>00-909</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-532</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Porto</city>
        <zip>4202-451</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bucharest</city>
        <zip>050653</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400046</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Alcorcon</city>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aravaca</city>
        <zip>28023</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Coslada</city>
        <zip>28820</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gijon</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>M√°laga</city>
        <zip>29007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Sebastian De Los Reyes</city>
        <zip>28702</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vigo</city>
        <zip>36211</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fowey</city>
        <state>Cornwall</state>
        <zip>PL23 1DT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Durham</city>
        <state>County Durham</state>
        <zip>DH1 2QW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <zip>PL6 7TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2010</study_first_submitted>
  <study_first_submitted_qc>May 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2010</study_first_posted>
  <results_first_submitted>June 11, 2012</results_first_submitted>
  <results_first_submitted_qc>September 18, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 19, 2012</results_first_posted>
  <last_update_submitted>September 18, 2012</last_update_submitted>
  <last_update_submitted_qc>September 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Erectile Dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tadalafil On Demand</title>
          <description>Participants were instructed to take a 10-milligram (mg) or 20-mg tablet of tadalafil orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Tadalafil Once a Day</title>
          <description>Participants were instructed to take a 5-mg or 2.5-mg tablet of tadalafil orally once a day for 24 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Sildenafil Citrate On Demand</title>
          <description>Participants were instructed to take a 50-mg, 100-mg, or 25-mg tablet of sildenafil citrate orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="252"/>
                <participants group_id="P2" count="257"/>
                <participants group_id="P3" count="261"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="250"/>
                <participants group_id="P2" count="257"/>
                <participants group_id="P3" count="260"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="220"/>
                <participants group_id="P2" count="228"/>
                <participants group_id="P3" count="214"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="47"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tadalafil On Demand</title>
          <description>Participants were instructed to take a 10-milligram (mg) or 20-mg tablet of tadalafil orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Tadalafil Once a Day</title>
          <description>Participants were instructed to take a 5-mg or 2.5-mg tablet of tadalafil orally once a day for 24 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Sildenafil Citrate On Demand</title>
          <description>Participants were instructed to take a 50-mg, 100-mg, or 25-mg tablet of sildenafil citrate orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="252"/>
            <count group_id="B2" value="257"/>
            <count group_id="B3" value="261"/>
            <count group_id="B4" value="770"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.2" spread="11.57"/>
                    <measurement group_id="B2" value="52.9" spread="11.69"/>
                    <measurement group_id="B3" value="53.0" spread="11.76"/>
                    <measurement group_id="B4" value="53.0" spread="11.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="252"/>
                    <measurement group_id="B2" value="257"/>
                    <measurement group_id="B3" value="261"/>
                    <measurement group_id="B4" value="770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="248"/>
                    <measurement group_id="B2" value="251"/>
                    <measurement group_id="B3" value="254"/>
                    <measurement group_id="B4" value="753"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Discontinuation of Randomized Treatment</title>
        <description>Time to discontinuation of randomized treatment was defined as the number of days from randomization until the day the participant discontinued the randomized treatment. Discontinuation of randomized treatment was defined as switching between the 3 study treatments (tadalafil on demand, tadalafil once a day, or sildenafil citrate on demand) or discontinuing from all treatments. A change of dose within the same treatment was not considered switching of treatment. This outcome measure was estimated using the Kaplan-Meier product-limit method.</description>
        <time_frame>Baseline up to 334 days</time_frame>
        <population>The analysis included all randomly assigned participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil On Demand</title>
            <description>Participants were instructed to take a 10-milligram (mg) or 20-mg tablet of tadalafil orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil Once a Day</title>
            <description>Participants were instructed to take a 5-mg or 2.5-mg tablet of tadalafil orally once a day for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Sildenafil Citrate On Demand</title>
            <description>Participants were instructed to take a 50-mg, 100-mg, or 25-mg tablet of sildenafil citrate orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Discontinuation of Randomized Treatment</title>
          <description>Time to discontinuation of randomized treatment was defined as the number of days from randomization until the day the participant discontinued the randomized treatment. Discontinuation of randomized treatment was defined as switching between the 3 study treatments (tadalafil on demand, tadalafil once a day, or sildenafil citrate on demand) or discontinuing from all treatments. A change of dose within the same treatment was not considered switching of treatment. This outcome measure was estimated using the Kaplan-Meier product-limit method.</description>
          <population>The analysis included all randomly assigned participants.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="257"/>
                <count group_id="O3" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="187">The median and the 95% confidence interval were not estimable because an insufficient number of participants reached the event at the time of the data cutoff.</measurement>
                    <measurement group_id="O2" value="130" lower_limit="113">The 95% confidence interval was not estimable because an insufficient number of participants reached the event at the time of the data cutoff.</measurement>
                    <measurement group_id="O3" value="67" lower_limit="64" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value: Tadalafil Once a Day versus Sildenafil Citrate On Demand treatment groups. Cox‚Äôs proportional hazards model with factors for randomized treatment group, baseline International Index of Erectile Function-Erectile Function score, and country.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.66</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value: Tadalafil On Demand versus Sildenafil Citrate On Demand treatment groups. Cox‚Äôs proportional hazards model with factors for randomized treatment group, baseline International Index of Erectile Function-Erectile Function score, and country.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.49</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>0.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.033</p_value>
            <p_value_desc>P-value: Tadalafil On Demand versus Tadalafil Once a Day treatment groups using Cox‚Äôs proportional hazards model with factors for randomized treatment group, baseline International Index of Erectile Function-Erectile Function score, and country.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>1.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Erectile Function (EF) Domain</title>
        <description>Self-reported EF score over past 4 weeks. Items 1-5 scores range from 0 (no sexual activity) to 5 (high EF). Item 15 score ranges from 1 (very low confidence to get/keep erection) to 5 (very high confidence). Total scores range from 1 to 30; lower scores denote greater erectile dysfunction severity. Least Squares Mean changes from baseline to endpoint for each visit from repeated measures analysis included terms for baseline score, treatment group, country, baseline*treatment (if p&lt;0.10), visit, and visit*treatment. Correlation matrix for repeated observations assumed to be unstructured.</description>
        <time_frame>Baseline, 4, 8, 16, and 24 weeks</time_frame>
        <population>The analysis included all randomly assigned participants who had a baseline and post-baseline IIEF-EF observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil On Demand</title>
            <description>Participants were instructed to take a 10-milligram (mg) or 20-mg tablet of tadalafil orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil Once a Day</title>
            <description>Participants were instructed to take a 5-mg or 2.5-mg tablet of tadalafil orally once a day for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Sildenafil Citrate On Demand</title>
            <description>Participants were instructed to take a 50-mg, 100-mg, or 25-mg tablet of sildenafil citrate orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Erectile Function (EF) Domain</title>
          <description>Self-reported EF score over past 4 weeks. Items 1-5 scores range from 0 (no sexual activity) to 5 (high EF). Item 15 score ranges from 1 (very low confidence to get/keep erection) to 5 (very high confidence). Total scores range from 1 to 30; lower scores denote greater erectile dysfunction severity. Least Squares Mean changes from baseline to endpoint for each visit from repeated measures analysis included terms for baseline score, treatment group, country, baseline*treatment (if p&lt;0.10), visit, and visit*treatment. Correlation matrix for repeated observations assumed to be unstructured.</description>
          <population>The analysis included all randomly assigned participants who had a baseline and post-baseline IIEF-EF observation.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="251"/>
                <count group_id="O3" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.92" spread="0.44"/>
                    <measurement group_id="O2" value="8.60" spread="0.43"/>
                    <measurement group_id="O3" value="8.86" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 8 (n=231, 232, 232)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.98" spread="0.45"/>
                    <measurement group_id="O2" value="9.08" spread="0.45"/>
                    <measurement group_id="O3" value="9.70" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 16 (n=167, 146, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.60" spread="0.41"/>
                    <measurement group_id="O2" value="9.93" spread="0.42"/>
                    <measurement group_id="O3" value="10.56" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 24 (n=141, 116, 81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.70" spread="0.43"/>
                    <measurement group_id="O2" value="10.01" spread="0.45"/>
                    <measurement group_id="O3" value="11.05" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Orgasmic Function Domain</title>
        <description>Self-reported orgasmic function on the IIEF over past 4 weeks and consists of 2 questions (items 9 and 10). Each question is rated on a scale from 0 (no sexual stimulation) to 5 (almost always/always). Total scores range from 0 to 10; lower scores represent lower orgasmic function. Least Squares Mean changes from baseline to endpoint for each visit were from a repeated measures analysis and included terms for baseline score, treatment group, country, baseline*treatment (if p&lt;0.10), visit, and visit*treatment. The correlation matrix for the repeated observations was assumed to be unstructured.</description>
        <time_frame>Baseline, 4, 8, 16, and 24 weeks</time_frame>
        <population>The analysis included all randomly assigned participants who had a baseline and post-baseline IIEF Orgasmic Function observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil On Demand</title>
            <description>Participants were instructed to take a 10-milligram (mg) or 20-mg tablet of tadalafil orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil Once a Day</title>
            <description>Participants were instructed to take a 5-mg or 2.5-mg tablet of tadalafil orally once a day for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Sildenafil Citrate On Demand</title>
            <description>Participants were instructed to take a 50-mg, 100-mg, or 25-mg tablet of sildenafil citrate orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Orgasmic Function Domain</title>
          <description>Self-reported orgasmic function on the IIEF over past 4 weeks and consists of 2 questions (items 9 and 10). Each question is rated on a scale from 0 (no sexual stimulation) to 5 (almost always/always). Total scores range from 0 to 10; lower scores represent lower orgasmic function. Least Squares Mean changes from baseline to endpoint for each visit were from a repeated measures analysis and included terms for baseline score, treatment group, country, baseline*treatment (if p&lt;0.10), visit, and visit*treatment. The correlation matrix for the repeated observations was assumed to be unstructured.</description>
          <population>The analysis included all randomly assigned participants who had a baseline and post-baseline IIEF Orgasmic Function observation.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="251"/>
                <count group_id="O3" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" spread="0.16"/>
                    <measurement group_id="O2" value="1.75" spread="0.16"/>
                    <measurement group_id="O3" value="1.92" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 8 (n=231, 232, 232)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread="0.16"/>
                    <measurement group_id="O2" value="2.08" spread="0.16"/>
                    <measurement group_id="O3" value="2.26" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 16 (n=167, 146, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.37" spread="0.15"/>
                    <measurement group_id="O2" value="2.25" spread="0.16"/>
                    <measurement group_id="O3" value="2.66" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 24 (n=141, 116, 81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.55" spread="0.15"/>
                    <measurement group_id="O2" value="2.48" spread="0.16"/>
                    <measurement group_id="O3" value="2.62" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Sexual Desire Domain</title>
        <description>Self-reported sexual desire on IIEF over past 4 weeks; comprises 2 questions (items 11 and 12). Each question rated on a scale from 1 (almost never or low/no sexual desire) to 5 (almost always or very high sexual desire). Total scores range: 2 to 10; lower numerical scores denote lower sexual desire. Least Squares Mean changes from baseline to endpoint for each visit from repeated measures analysis and included terms for baseline score, treatment group, country, baseline*treatment (if p&lt;0.10), visit, and visit*treatment. Correlation matrix for repeated observations assumed to be unstructured.</description>
        <time_frame>Baseline, 4, 8, 16, and 24 weeks</time_frame>
        <population>The analysis included all randomly assigned participants who had a baseline and post-baseline IIEF Sexual Desire observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil On Demand</title>
            <description>Participants were instructed to take a 10-milligram (mg) or 20-mg tablet of tadalafil orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil Once a Day</title>
            <description>Participants were instructed to take a 5-mg or 2.5-mg tablet of tadalafil orally once a day for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Sildenafil Citrate On Demand</title>
            <description>Participants were instructed to take a 50-mg, 100-mg, or 25-mg tablet of sildenafil citrate orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Sexual Desire Domain</title>
          <description>Self-reported sexual desire on IIEF over past 4 weeks; comprises 2 questions (items 11 and 12). Each question rated on a scale from 1 (almost never or low/no sexual desire) to 5 (almost always or very high sexual desire). Total scores range: 2 to 10; lower numerical scores denote lower sexual desire. Least Squares Mean changes from baseline to endpoint for each visit from repeated measures analysis and included terms for baseline score, treatment group, country, baseline*treatment (if p&lt;0.10), visit, and visit*treatment. Correlation matrix for repeated observations assumed to be unstructured.</description>
          <population>The analysis included all randomly assigned participants who had a baseline and post-baseline IIEF Sexual Desire observation.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="250"/>
                <count group_id="O3" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to 4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.10"/>
                    <measurement group_id="O2" value="0.75" spread="0.10"/>
                    <measurement group_id="O3" value="0.69" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to 8 Weeks (n=230, 232, 232)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" spread="0.11"/>
                    <measurement group_id="O2" value="0.90" spread="0.11"/>
                    <measurement group_id="O3" value="0.87" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to 16 Weeks (n=167, 146, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="0.12"/>
                    <measurement group_id="O2" value="0.87" spread="0.12"/>
                    <measurement group_id="O3" value="1.07" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to 24 Weeks (n=140, 117, 81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" spread="0.12"/>
                    <measurement group_id="O2" value="0.78" spread="0.13"/>
                    <measurement group_id="O3" value="1.29" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 4, 8, 16 and 24 Weeks of the Sexual Encounter Profile (SEP)</title>
        <description>Participant-assessed diary. Has 5 questions (Question[Q]1:erection achievement, Q2:successful penetration, Q3:successful intercourse, Q4:satisfied with erection, and Q5:satisfied with sexual experience) for each sexual encounter made over specified period of time. SEP Q1-Q5 scores determined as percentage of 'Yes' responses to each of 5 questions out of all sexual attempts recorded during the time period. Least Squares Mean changes from baseline to endpoint for each visit from a repeated measures analysis included terms for baseline score, treatment group, country, visit, and visit*treatment.</description>
        <time_frame>Baseline, 4, 8, 16, and 24 weeks</time_frame>
        <population>The analysis included all randomly assigned participants who had a baseline and post-baseline SEP observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil On Demand</title>
            <description>Participants were instructed to take a 10-milligram (mg) or 20-mg tablet of tadalafil orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil Once a Day</title>
            <description>Participants were instructed to take a 5-mg or 2.5-mg tablet of tadalafil orally once a day for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Sildenafil Citrate On Demand</title>
            <description>Participants were instructed to take a 50-mg, 100-mg, or 25-mg tablet of sildenafil citrate orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 4, 8, 16 and 24 Weeks of the Sexual Encounter Profile (SEP)</title>
          <description>Participant-assessed diary. Has 5 questions (Question[Q]1:erection achievement, Q2:successful penetration, Q3:successful intercourse, Q4:satisfied with erection, and Q5:satisfied with sexual experience) for each sexual encounter made over specified period of time. SEP Q1-Q5 scores determined as percentage of 'Yes' responses to each of 5 questions out of all sexual attempts recorded during the time period. Least Squares Mean changes from baseline to endpoint for each visit from a repeated measures analysis included terms for baseline score, treatment group, country, visit, and visit*treatment.</description>
          <population>The analysis included all randomly assigned participants who had a baseline and post-baseline SEP observation.</population>
          <units>percentage of &quot;yes&quot; responses</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="246"/>
                <count group_id="O3" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Q1:Change from Baseline to 4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.50" lower_limit="11.82" upper_limit="17.18"/>
                    <measurement group_id="O2" value="18.49" lower_limit="15.83" upper_limit="21.14"/>
                    <measurement group_id="O3" value="18.41" lower_limit="15.77" upper_limit="21.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q1:Change from Baseline to 8 Weeks (n=224,231,229)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.62" lower_limit="14.05" upper_limit="19.19"/>
                    <measurement group_id="O2" value="19.88" lower_limit="17.33" upper_limit="22.43"/>
                    <measurement group_id="O3" value="20.41" lower_limit="17.87" upper_limit="22.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q1:Change from Baseline to 16 Weeks (n=166,146,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.46" lower_limit="16.02" upper_limit="20.89"/>
                    <measurement group_id="O2" value="19.19" lower_limit="16.72" upper_limit="21.67"/>
                    <measurement group_id="O3" value="20.58" lower_limit="17.90" upper_limit="23.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q1:Change from Baseline to 24 Weeks (n=139,115,81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.97" lower_limit="17.78" upper_limit="22.15"/>
                    <measurement group_id="O2" value="19.60" lower_limit="17.33" upper_limit="21.86"/>
                    <measurement group_id="O3" value="20.34" lower_limit="17.94" upper_limit="22.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q2:Change from Baseline to 4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.48" lower_limit="23.77" upper_limit="31.19"/>
                    <measurement group_id="O2" value="28.56" lower_limit="24.87" upper_limit="32.24"/>
                    <measurement group_id="O3" value="29.64" lower_limit="25.96" upper_limit="33.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q2:Change from Baseline to 8 Weeks (n=224,231,229)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.16" lower_limit="27.57" upper_limit="34.76"/>
                    <measurement group_id="O2" value="31.66" lower_limit="28.09" upper_limit="35.22"/>
                    <measurement group_id="O3" value="34.08" lower_limit="30.52" upper_limit="37.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q2:Change from Baseline to 16 Weeks (n=166,146,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.76" lower_limit="29.38" upper_limit="36.14"/>
                    <measurement group_id="O2" value="32.76" lower_limit="29.33" upper_limit="36.20"/>
                    <measurement group_id="O3" value="36.07" lower_limit="32.38" upper_limit="39.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q2:Change from Baseline to 24 Weeks (n=139,115,81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.83" lower_limit="32.71" upper_limit="38.94"/>
                    <measurement group_id="O2" value="34.70" lower_limit="31.48" upper_limit="37.92"/>
                    <measurement group_id="O3" value="35.93" lower_limit="32.51" upper_limit="39.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q3:Change from Baseline to 4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.52" lower_limit="36.79" upper_limit="46.26"/>
                    <measurement group_id="O2" value="41.76" lower_limit="37.05" upper_limit="46.47"/>
                    <measurement group_id="O3" value="44.45" lower_limit="39.76" upper_limit="49.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q3:Change from Baseline to 8 Weeks (n=224,231,229)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.45" lower_limit="42.65" upper_limit="52.26"/>
                    <measurement group_id="O2" value="44.58" lower_limit="39.80" upper_limit="49.35"/>
                    <measurement group_id="O3" value="52.11" lower_limit="47.36" upper_limit="56.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q3:Change from Baseline to 16 Weeks (n=166,146,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.26" lower_limit="49.86" upper_limit="58.67"/>
                    <measurement group_id="O2" value="50.62" lower_limit="46.14" upper_limit="55.11"/>
                    <measurement group_id="O3" value="56.96" lower_limit="52.10" upper_limit="61.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q3:Change from Baseline to 24 Weeks (n=139,115,81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.39" lower_limit="51.89" upper_limit="60.89"/>
                    <measurement group_id="O2" value="53.83" lower_limit="49.13" upper_limit="58.53"/>
                    <measurement group_id="O3" value="56.28" lower_limit="51.18" upper_limit="61.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q4:Change from Baseline to 4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.59" lower_limit="44.22" upper_limit="54.97"/>
                    <measurement group_id="O2" value="51.78" lower_limit="46.44" upper_limit="57.12"/>
                    <measurement group_id="O3" value="51.45" lower_limit="46.13" upper_limit="56.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q4:Change from Baseline to 8 Weeks (n=224,231,229)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.86" lower_limit="55.37" upper_limit="66.36"/>
                    <measurement group_id="O2" value="55.59" lower_limit="50.14" upper_limit="61.05"/>
                    <measurement group_id="O3" value="59.28" lower_limit="53.85" upper_limit="64.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q4:Change from Baseline to 16 Weeks (n=166,146,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.17" lower_limit="60.92" upper_limit="71.43"/>
                    <measurement group_id="O2" value="63.00" lower_limit="57.64" upper_limit="68.36"/>
                    <measurement group_id="O3" value="66.48" lower_limit="60.65" upper_limit="72.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q4:Change from Baseline to 24 Weeks (n=139,115,81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.67" lower_limit="67.46" upper_limit="77.89"/>
                    <measurement group_id="O2" value="68.06" lower_limit="62.58" upper_limit="73.54"/>
                    <measurement group_id="O3" value="69.04" lower_limit="63.06" upper_limit="75.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q5:Change from Baseline to 4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.12" lower_limit="40.79" upper_limit="51.46"/>
                    <measurement group_id="O2" value="45.71" lower_limit="40.41" upper_limit="51.01"/>
                    <measurement group_id="O3" value="49.63" lower_limit="44.35" upper_limit="54.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q5:Change from Baseline to 8 Weeks (n=224,231,229)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.92" lower_limit="48.46" upper_limit="59.37"/>
                    <measurement group_id="O2" value="50.06" lower_limit="44.65" upper_limit="55.47"/>
                    <measurement group_id="O3" value="55.73" lower_limit="50.33" upper_limit="61.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q5:Change from Baseline to 16 Weeks (n=166,146,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.57" lower_limit="56.26" upper_limit="66.88"/>
                    <measurement group_id="O2" value="54.56" lower_limit="49.16" upper_limit="59.96"/>
                    <measurement group_id="O3" value="62.40" lower_limit="56.55" upper_limit="68.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q5:Change from Baseline to 24 Weeks (n=139,115,81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.45" lower_limit="60.29" upper_limit="70.60"/>
                    <measurement group_id="O2" value="62.17" lower_limit="56.78" upper_limit="67.57"/>
                    <measurement group_id="O3" value="66.57" lower_limit="60.72" upper_limit="72.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Assessment Questions (GAQ)</title>
        <description>The GAQ consists of 2 Yes/No/No Response (No Respo) questions. GAQ Question (Q)1: Has the treatment you have been taking during this study improved your erections? GAQ Q2: Has the treatment improved your ability to engage in sexual activity?</description>
        <time_frame>24 weeks</time_frame>
        <population>The analysis included all randomly assigned participants. The last available GAQ assessment for each participant was used in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil On Demand</title>
            <description>Participants were instructed to take a 10-milligram (mg) or 20-mg tablet of tadalafil orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil Once a Day</title>
            <description>Participants were instructed to take a 5-mg or 2.5-mg tablet of tadalafil orally once a day for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Sildenafil Citrate On Demand</title>
            <description>Participants were instructed to take a 50-mg, 100-mg, or 25-mg tablet of sildenafil citrate orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Global Assessment Questions (GAQ)</title>
          <description>The GAQ consists of 2 Yes/No/No Response (No Respo) questions. GAQ Question (Q)1: Has the treatment you have been taking during this study improved your erections? GAQ Q2: Has the treatment improved your ability to engage in sexual activity?</description>
          <population>The analysis included all randomly assigned participants. The last available GAQ assessment for each participant was used in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="257"/>
                <count group_id="O3" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Q1:Treatment improved erections? Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                    <measurement group_id="O2" value="219"/>
                    <measurement group_id="O3" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q1:Treatment improved erections? No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q1: Treatment improved erections? No Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q2:Treatment improved ability to engage? Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209"/>
                    <measurement group_id="O2" value="214"/>
                    <measurement group_id="O3" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q2:Treatment improved ability to engage? No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q2: Treatment improved ability to engage? No Respo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Treatment Switches</title>
        <description>The number of times participants switched erectile dysfunction medication within the 3 treatments being studied (tadalafil on demand, tadalafil once a day, or sildenafil citrate on demand).</description>
        <time_frame>Baseline through 24 weeks</time_frame>
        <population>The analysis included all randomly assigned participants who switched erectile dysfunction medication and had a baseline and post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil On Demand</title>
            <description>Participants were instructed to take a 10-milligram (mg) or 20-mg tablet of tadalafil orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil Once a Day</title>
            <description>Participants were instructed to take a 5-mg or 2.5-mg tablet of tadalafil orally once a day for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Sildenafil Citrate On Demand</title>
            <description>Participants were instructed to take a 50-mg, 100-mg, or 25-mg tablet of sildenafil citrate orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Treatment Switches</title>
          <description>The number of times participants switched erectile dysfunction medication within the 3 treatments being studied (tadalafil on demand, tadalafil once a day, or sildenafil citrate on demand).</description>
          <population>The analysis included all randomly assigned participants who switched erectile dysfunction medication and had a baseline and post-baseline observation.</population>
          <units>number of treatment switches</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.4"/>
                    <measurement group_id="O2" value="1.2" spread="0.5"/>
                    <measurement group_id="O3" value="1.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patterns of Erectile Dysfunction Treatment Change</title>
        <description>Results are reported as the number of participants per sequence of study medications (tadalafil on demand, tadalafil once a day, or sildenafil citrate on demand) that were taken as a result of switching treatments. The Other Treatment Sequence reports the number of participants per sequence of study medications that were taken as a result of switching treatments more than once. The number of participants who did not switch is also reported.</description>
        <time_frame>Baseline through 24 weeks</time_frame>
        <population>All randomly assigned participants were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Entire Study Population</title>
            <description>Tadalafil On Demand: Participants were instructed to take a 10-milligram (mg) or 20-mg tablet of tadalafil orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day).
Tadalafil Once a Day: Participants were instructed to take a 5-mg or 2.5-mg tadalafil tablet orally, once a day.
Sildenafil Citrate On Demand: Participants were instructed to take a 50-mg, 100-mg, or 25-mg tablet of sildenafil citrate orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day).</description>
          </group>
        </group_list>
        <measure>
          <title>Patterns of Erectile Dysfunction Treatment Change</title>
          <description>Results are reported as the number of participants per sequence of study medications (tadalafil on demand, tadalafil once a day, or sildenafil citrate on demand) that were taken as a result of switching treatments. The Other Treatment Sequence reports the number of participants per sequence of study medications that were taken as a result of switching treatments more than once. The number of participants who did not switch is also reported.</description>
          <population>All randomly assigned participants were included in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="770"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No Treatment Intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Switch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>From Once a Day to Any On Demand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>From Any On Demand to Once a Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>From Any On Demand to Any On Demand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Returning Back to Randomized Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Treatment Sequence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reasons for Discontinuation of Randomized Erectile Dysfunction Treatment</title>
        <description>The reported reasons for a decision to discontinue from initial randomized treatment prior to Week 24 are reported. Discontinuation of randomized treatment was defined as switching between the 3 study treatments (tadalafil on demand, tadalafil once a day, or sildenafil citrate on demand) or discontinuing from all treatments. A change of dose within the same treatment was not considered as switching of treatment.</description>
        <time_frame>Baseline through 24 weeks</time_frame>
        <population>The analysis included all randomly assigned participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil On Demand</title>
            <description>Participants were instructed to take a 10-milligram (mg) or 20-mg tablet of tadalafil orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil Once a Day</title>
            <description>Participants were instructed to take a 5-mg or 2.5-mg tablet of tadalafil orally once a day for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Sildenafil Citrate On Demand</title>
            <description>Participants were instructed to take a 50-mg, 100-mg, or 25-mg tablet of sildenafil citrate orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Reasons for Discontinuation of Randomized Erectile Dysfunction Treatment</title>
          <description>The reported reasons for a decision to discontinue from initial randomized treatment prior to Week 24 are reported. Discontinuation of randomized treatment was defined as switching between the 3 study treatments (tadalafil on demand, tadalafil once a day, or sildenafil citrate on demand) or discontinuing from all treatments. A change of dose within the same treatment was not considered as switching of treatment.</description>
          <population>The analysis included all randomly assigned participants.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="257"/>
                <count group_id="O3" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Slow onset of action</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Completed treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lack of efficacy (hardness of erection)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lack of efficacy (duration of erection)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lack of confidence in medication working each time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feel medication controls my sexual life</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-desired spontaneous erections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time constraints due to short drug action window</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partner's request</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Don't want to take a pill every day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prefer a pill every day, not on demand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant discontinuation from the trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant did not take any study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants without discontinuation event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="122"/>
                    <measurement group_id="O3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days From the 8-Week Study Visit to the Time the Participant Discontinues From All Phosphodiesterase Type 5 (PDE5) Inhibitor Treatments</title>
        <description>The differences in time between the 8-week time point and the discontinuation of all study treatments (that is, discontinuation from the study and not switching to another treatment) are reported by the median (95% confidence interval). Duration was measured as the number of days from Week 8 to the date of the last dose of the study drug. This outcome measure was estimated using the Kaplan-Meier product-limit method.</description>
        <time_frame>8 weeks up to 334 days</time_frame>
        <population>The analysis included all randomly assigned participants who completed the 8-week randomized treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil On Demand</title>
            <description>Participants were instructed to take a 10-milligram (mg) or 20-mg tablet of tadalafil orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day).</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil Once a Day</title>
            <description>Participants were instructed to take a 5-mg or 2.5-mg tadalafil tablet orally, once a day.</description>
          </group>
          <group group_id="O3">
            <title>Sildenafil Citrate On Demand</title>
            <description>Participants were instructed to take a 50-mg, 100-mg, or 25-mg tablet of sildenafil citrate orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days From the 8-Week Study Visit to the Time the Participant Discontinues From All Phosphodiesterase Type 5 (PDE5) Inhibitor Treatments</title>
          <description>The differences in time between the 8-week time point and the discontinuation of all study treatments (that is, discontinuation from the study and not switching to another treatment) are reported by the median (95% confidence interval). Duration was measured as the number of days from Week 8 to the date of the last dose of the study drug. This outcome measure was estimated using the Kaplan-Meier product-limit method.</description>
          <population>The analysis included all randomly assigned participants who completed the 8-week randomized treatment.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="238"/>
                <count group_id="O3" value="236"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median and the 95% confidence interval were not estimable because an insufficient number of participants reached the event at the time of the data cutoff.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="200">The median and the 95% confidence interval were not estimable because an insufficient number of participants reached the event at the time of the data cutoff.</measurement>
                    <measurement group_id="O3" value="187" lower_limit="165">The 95% confidence interval was not estimable because an insufficient number of participants reached the event at the time of the data cutoff.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Intercourse Satisfaction Domain</title>
        <description>Self-reported intercourse satisfaction score over past 4 weeks (1 intercourse attempt item, 2 intercourse satisfaction items). Each item range: 0 (no intercourse attempts/no satisfaction) to 5 (more attempts/high satisfaction). Total scores range: 0-15; lower scores=lower intercourse satisfaction. Least Squares Mean changes from baseline to endpoint for each visit from repeated measures analysis and included terms for baseline score, treatment group, country, baseline*treatment (if p&lt;0.10), visit, and visit*treatment. Correlation matrix for repeated observations assumed to be unstructured.</description>
        <time_frame>Baseline, 4, 8, 16, and 24 weeks</time_frame>
        <population>The analysis included all randomly assigned participants who had a baseline and post-baseline IIEF Intercourse Satisfaction observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil On Demand</title>
            <description>Participants were instructed to take a 10-milligram (mg) or 20-mg tablet of tadalafil orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil Once a Day</title>
            <description>Participants were instructed to take a 5-mg or 2.5-mg tablet of tadalafil orally once a day for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Sildenafil Citrate On Demand</title>
            <description>Participants were instructed to take a 50-mg, 100-mg, or 25-mg tablet of sildenafil citrate orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Intercourse Satisfaction Domain</title>
          <description>Self-reported intercourse satisfaction score over past 4 weeks (1 intercourse attempt item, 2 intercourse satisfaction items). Each item range: 0 (no intercourse attempts/no satisfaction) to 5 (more attempts/high satisfaction). Total scores range: 0-15; lower scores=lower intercourse satisfaction. Least Squares Mean changes from baseline to endpoint for each visit from repeated measures analysis and included terms for baseline score, treatment group, country, baseline*treatment (if p&lt;0.10), visit, and visit*treatment. Correlation matrix for repeated observations assumed to be unstructured.</description>
          <population>The analysis included all randomly assigned participants who had a baseline and post-baseline IIEF Intercourse Satisfaction observation.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="251"/>
                <count group_id="O3" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.21" spread="0.20"/>
                    <measurement group_id="O2" value="3.22" spread="0.20"/>
                    <measurement group_id="O3" value="3.53" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 8 (n=231, 232, 232)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.69" spread="0.20"/>
                    <measurement group_id="O2" value="3.15" spread="0.20"/>
                    <measurement group_id="O3" value="3.95" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 16 (n=167, 146, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.38" spread="0.20"/>
                    <measurement group_id="O2" value="3.60" spread="0.21"/>
                    <measurement group_id="O3" value="4.41" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 24 (n=141, 116, 81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.48" spread="0.21"/>
                    <measurement group_id="O2" value="3.71" spread="0.22"/>
                    <measurement group_id="O3" value="4.70" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Overall Satisfaction Domain</title>
        <description>Self-reported overall satisfaction on the IIEF over past 4 weeks and consists of 2 questions (items 13 and 14), each rated on a scale from 1 (very dissatisfied) to 5 (very satisfied). Total scores range from 2 to 10; lower numerical scores represent lower overall satisfaction. Least Squares Mean changes from baseline to endpoint for each visit were from a repeated measures analysis and included terms for baseline score, treatment group, country, baseline*treatment (if p&lt;0.10), visit, and visit*treatment. The correlation matrix for the repeated observations was assumed to be unstructured.</description>
        <time_frame>Baseline, 4, 8, 16, and 24 weeks</time_frame>
        <population>The analysis included all randomly assigned participants who had a baseline and post-baseline IIEF Overall Satisfaction observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil On Demand</title>
            <description>Participants were instructed to take a 10-milligram (mg) or 20-mg tablet of tadalafil orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil Once a Day</title>
            <description>Participants were instructed to take a 5-mg or 2.5-mg tablet of tadalafil orally once a day for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Sildenafil Citrate On Demand</title>
            <description>Participants were instructed to take a 50-mg, 100-mg, or 25-mg tablet of sildenafil citrate orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Overall Satisfaction Domain</title>
          <description>Self-reported overall satisfaction on the IIEF over past 4 weeks and consists of 2 questions (items 13 and 14), each rated on a scale from 1 (very dissatisfied) to 5 (very satisfied). Total scores range from 2 to 10; lower numerical scores represent lower overall satisfaction. Least Squares Mean changes from baseline to endpoint for each visit were from a repeated measures analysis and included terms for baseline score, treatment group, country, baseline*treatment (if p&lt;0.10), visit, and visit*treatment. The correlation matrix for the repeated observations was assumed to be unstructured.</description>
          <population>The analysis included all randomly assigned participants who had a baseline and post-baseline IIEF Overall Satisfaction observation.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="250"/>
                <count group_id="O3" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.46" spread="0.16"/>
                    <measurement group_id="O2" value="2.58" spread="0.15"/>
                    <measurement group_id="O3" value="2.72" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 8 (n=230, 231, 233)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.80" spread="0.16"/>
                    <measurement group_id="O2" value="2.85" spread="0.16"/>
                    <measurement group_id="O3" value="2.98" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 16 (n=167, 145, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.34" spread="0.15"/>
                    <measurement group_id="O2" value="3.09" spread="0.15"/>
                    <measurement group_id="O3" value="3.48" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 24 (n=141, 116, 81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.50" spread="0.15"/>
                    <measurement group_id="O2" value="3.24" spread="0.16"/>
                    <measurement group_id="O3" value="3.41" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire at 4, 8, 16, and 24 Weeks</title>
        <description>The participant questionnaire consists of 11 questions. Each question is rated on a scale of 0 (extremely low treatment satisfaction) to 4 (extremely high treatment satisfaction). The EDITS summary score was obtained by adding each individual result for all questions, dividing by the number of questions answered (mean satisfaction score), then multiplying by 25, thus obtaining a score range from 0 (extremely low treatment satisfaction) to 100 (extremely high satisfaction). Least Squares Mean changes were adjusted for treatment group, country, visit, and visit*treatment.</description>
        <time_frame>4, 8, 16, and 24 weeks</time_frame>
        <population>The analysis included all randomly assigned participants who had a baseline and post-baseline EDITS observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil On Demand</title>
            <description>Participants were instructed to take a 10-milligram (mg) or 20-mg tablet of tadalafil orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil Once a Day</title>
            <description>Participants were instructed to take a 5-mg or 2.5-mg tablet of tadalafil orally once a day for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Sildenafil Citrate On Demand</title>
            <description>Participants were instructed to take a 50-mg, 100-mg, or 25-mg tablet of sildenafil citrate orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire at 4, 8, 16, and 24 Weeks</title>
          <description>The participant questionnaire consists of 11 questions. Each question is rated on a scale of 0 (extremely low treatment satisfaction) to 4 (extremely high treatment satisfaction). The EDITS summary score was obtained by adding each individual result for all questions, dividing by the number of questions answered (mean satisfaction score), then multiplying by 25, thus obtaining a score range from 0 (extremely low treatment satisfaction) to 100 (extremely high satisfaction). Least Squares Mean changes were adjusted for treatment group, country, visit, and visit*treatment.</description>
          <population>The analysis included all randomly assigned participants who had a baseline and post-baseline EDITS observation.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="252"/>
                <count group_id="O3" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EDITS at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.36" lower_limit="69.64" upper_limit="75.08"/>
                    <measurement group_id="O2" value="75.20" lower_limit="72.51" upper_limit="77.90"/>
                    <measurement group_id="O3" value="71.98" lower_limit="69.28" upper_limit="74.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EDITS at Week 8 (n=231, 235, 231)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.28" lower_limit="72.51" upper_limit="78.05"/>
                    <measurement group_id="O2" value="76.64" lower_limit="73.88" upper_limit="79.39"/>
                    <measurement group_id="O3" value="72.74" lower_limit="69.99" upper_limit="75.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EDITS at Week 16 (n=168, 147, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.64" lower_limit="77.00" upper_limit="82.29"/>
                    <measurement group_id="O2" value="77.66" lower_limit="74.97" upper_limit="80.35"/>
                    <measurement group_id="O3" value="76.64" lower_limit="73.71" upper_limit="79.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EDITS at Week 24 (n=141, 118, 80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.01" lower_limit="78.44" upper_limit="83.58"/>
                    <measurement group_id="O2" value="78.75" lower_limit="76.10" upper_limit="81.41"/>
                    <measurement group_id="O3" value="77.98" lower_limit="75.09" upper_limit="80.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 24 Week Endpoint of the Sexual Self-Confidence, Spontaneity, and Time Concerns Domains (23-items) of the Psychological and Interpersonal Relationships Scale (PAIRS)</title>
        <description>The PAIRS is a 23-item scale that assesses broader psychological/interpersonal outcomes associated with erectile dysfunction and its treatment. Each question is rated on a Likert scale from 1 (strongly disagree) to 4 (strongly agree). The scale consists of 3 domains: Sexual Self-Confidence (items 1-6), Spontaneity domain (items 7-15), and Time Concerns (items 16-23). The average domain score for each domain was calculated by adding the nonmissing items for the respective domain, then dividing by the number of nonmissing items for the respective domain. Each average domain score ranged from 1 to 4. Higher scores represent the following: greater sexual self-confidence (better outcome); greater spontaneity (better outcome); higher time concerns (worse outcome). The Least Squares Mean changes were adjusted for treatment group, country, baseline IIEF-EF severity, baseline domain score, and baseline domain score*treatment (if p&lt;0.10).</description>
        <time_frame>Baseline, 24 weeks</time_frame>
        <population>The analysis included all randomly assigned participants who had a baseline and post-baseline PAIRS observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil On Demand</title>
            <description>Participants were instructed to take a 10-milligram (mg) or 20-mg tablet of tadalafil orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil Once a Day</title>
            <description>Participants were instructed to take a 5-mg or 2.5-mg tablet of tadalafil orally once a day for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Sildenafil Citrate On Demand</title>
            <description>Participants were instructed to take a 50-mg, 100-mg, or 25-mg tablet of sildenafil citrate orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 24 Week Endpoint of the Sexual Self-Confidence, Spontaneity, and Time Concerns Domains (23-items) of the Psychological and Interpersonal Relationships Scale (PAIRS)</title>
          <description>The PAIRS is a 23-item scale that assesses broader psychological/interpersonal outcomes associated with erectile dysfunction and its treatment. Each question is rated on a Likert scale from 1 (strongly disagree) to 4 (strongly agree). The scale consists of 3 domains: Sexual Self-Confidence (items 1-6), Spontaneity domain (items 7-15), and Time Concerns (items 16-23). The average domain score for each domain was calculated by adding the nonmissing items for the respective domain, then dividing by the number of nonmissing items for the respective domain. Each average domain score ranged from 1 to 4. Higher scores represent the following: greater sexual self-confidence (better outcome); greater spontaneity (better outcome); higher time concerns (worse outcome). The Least Squares Mean changes were adjusted for treatment group, country, baseline IIEF-EF severity, baseline domain score, and baseline domain score*treatment (if p&lt;0.10).</description>
          <population>The analysis included all randomly assigned participants who had a baseline and post-baseline PAIRS observation.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="257"/>
                <count group_id="O3" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sexual Self-Confidence Domain (n=196, 203, 185)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" lower_limit="0.83" upper_limit="1.03"/>
                    <measurement group_id="O2" value="0.90" lower_limit="0.81" upper_limit="1.00"/>
                    <measurement group_id="O3" value="0.73" lower_limit="0.64" upper_limit="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spontaneity Domain (n=197, 202, 186)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" lower_limit="0.07" upper_limit="0.20"/>
                    <measurement group_id="O2" value="0.11" lower_limit="0.04" upper_limit="0.18"/>
                    <measurement group_id="O3" value="0.02" lower_limit="-0.05" upper_limit="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Concerns Domain (n=196, 200, 184)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" lower_limit="-0.16" upper_limit="-0.01"/>
                    <measurement group_id="O2" value="-0.20" lower_limit="-0.27" upper_limit="-0.12"/>
                    <measurement group_id="O3" value="0.04" lower_limit="-0.03" upper_limit="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 4, 8, 16, and 24 Weeks of the Sexual Relationship Domain of the Self-Esteem and Relationship (SEAR) Questionnaire</title>
        <description>SEAR assesses psychosocial outcomes in men with erectile dysfunction. Sexual Relationship domain consists of 8 items (items 1-8). Items 2-8 are rated on a scale of 1 (Never) to 5 (Always), whereas item 1 is reverse scored (1=Always and 5=Never). The domain score was computed by summing its respective items, then transforming it into a 0 (least favorable) to 100 (most favorable) scale. Transformed score = 100 x [(actual raw score - lowest possible raw score)/possible raw score range]. Least Squares Mean changes adjusted for baseline score, treatment group, country, visit, and visit*treatment.</description>
        <time_frame>Baseline, 4, 8, 16, and 24 weeks</time_frame>
        <population>The analysis included all randomly assigned participants who had a baseline and post-baseline SEAR Sexual Relationship observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil On Demand</title>
            <description>Participants were instructed to take a 10-milligram (mg) or 20-mg tablet of tadalafil orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil Once a Day</title>
            <description>Participants were instructed to take a 5-mg or 2.5-mg tablet of tadalafil orally once a day for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Sildenafil Citrate On Demand</title>
            <description>Participants were instructed to take a 50-mg, 100-mg, or 25-mg tablet of sildenafil citrate orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 4, 8, 16, and 24 Weeks of the Sexual Relationship Domain of the Self-Esteem and Relationship (SEAR) Questionnaire</title>
          <description>SEAR assesses psychosocial outcomes in men with erectile dysfunction. Sexual Relationship domain consists of 8 items (items 1-8). Items 2-8 are rated on a scale of 1 (Never) to 5 (Always), whereas item 1 is reverse scored (1=Always and 5=Never). The domain score was computed by summing its respective items, then transforming it into a 0 (least favorable) to 100 (most favorable) scale. Transformed score = 100 x [(actual raw score - lowest possible raw score)/possible raw score range]. Least Squares Mean changes adjusted for baseline score, treatment group, country, visit, and visit*treatment.</description>
          <population>The analysis included all randomly assigned participants who had a baseline and post-baseline SEAR Sexual Relationship observation.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="250"/>
                <count group_id="O3" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.65" lower_limit="24.65" upper_limit="30.65"/>
                    <measurement group_id="O2" value="29.26" lower_limit="26.29" upper_limit="32.23"/>
                    <measurement group_id="O3" value="29.50" lower_limit="26.53" upper_limit="32.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 8 (n=230, 232, 231)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.42" lower_limit="28.23" upper_limit="34.61"/>
                    <measurement group_id="O2" value="31.07" lower_limit="27.90" upper_limit="34.24"/>
                    <measurement group_id="O3" value="31.15" lower_limit="27.99" upper_limit="34.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 16 (n=167, 146, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.59" lower_limit="34.58" upper_limit="40.61"/>
                    <measurement group_id="O2" value="32.90" lower_limit="29.84" upper_limit="35.96"/>
                    <measurement group_id="O3" value="37.32" lower_limit="34.03" upper_limit="40.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 24 (n=140, 117, 81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.37" lower_limit="36.31" upper_limit="42.43"/>
                    <measurement group_id="O2" value="34.96" lower_limit="31.79" upper_limit="38.13"/>
                    <measurement group_id="O3" value="37.46" lower_limit="34.05" upper_limit="40.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 4, 8, 16, and 24 Weeks of the Confidence Domain of the Self-Esteem and Relationship (SEAR) Questionnaire</title>
        <description>SEAR assesses psychosocial outcomes in men with erectile dysfunction. Confidence domain measures improvement in confidence; 2 subscales (6 items: Self-Esteem [items 9-12]; Overall Relationship [items 13-14]). Each item range: 1 (Never) to 5 (Always); item 11 reverse scored. Domain score=sum of domain's respective items, then transformed into 0 (least favorable) to 100 (most favorable) scale. Transformed score=100x[(actual raw score-lowest possible raw score)/possible raw score range]. Least Squares Mean change adjusted for baseline score, treatment group, country, visit, and visit*treatment.</description>
        <time_frame>Baseline, 4, 8, 16, and 24 weeks</time_frame>
        <population>The analysis included all randomly assigned participants who had a baseline and post-baseline SEAR Confidence observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil On Demand</title>
            <description>Participants were instructed to take a 10-milligram (mg) or 20-mg tablet of tadalafil orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil Once a Day</title>
            <description>Participants were instructed to take a 5-mg or 2.5-mg tablet of tadalafil orally once a day for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Sildenafil Citrate On Demand</title>
            <description>Participants were instructed to take a 50-mg, 100-mg, or 25-mg tablet of sildenafil citrate orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 4, 8, 16, and 24 Weeks of the Confidence Domain of the Self-Esteem and Relationship (SEAR) Questionnaire</title>
          <description>SEAR assesses psychosocial outcomes in men with erectile dysfunction. Confidence domain measures improvement in confidence; 2 subscales (6 items: Self-Esteem [items 9-12]; Overall Relationship [items 13-14]). Each item range: 1 (Never) to 5 (Always); item 11 reverse scored. Domain score=sum of domain's respective items, then transformed into 0 (least favorable) to 100 (most favorable) scale. Transformed score=100x[(actual raw score-lowest possible raw score)/possible raw score range]. Least Squares Mean change adjusted for baseline score, treatment group, country, visit, and visit*treatment.</description>
          <population>The analysis included all randomly assigned participants who had a baseline and post-baseline SEAR Confidence observation.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="251"/>
                <count group_id="O3" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.43" lower_limit="20.32" upper_limit="26.54"/>
                    <measurement group_id="O2" value="23.04" lower_limit="19.96" upper_limit="26.13"/>
                    <measurement group_id="O3" value="25.03" lower_limit="21.94" upper_limit="28.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 8 (n=230, 233, 232)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.97" lower_limit="23.83" upper_limit="30.11"/>
                    <measurement group_id="O2" value="26.10" lower_limit="22.97" upper_limit="29.22"/>
                    <measurement group_id="O3" value="27.14" lower_limit="24.03" upper_limit="30.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 16 (n=167, 147, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.15" lower_limit="30.28" upper_limit="36.02"/>
                    <measurement group_id="O2" value="28.33" lower_limit="25.41" upper_limit="31.25"/>
                    <measurement group_id="O3" value="31.86" lower_limit="28.71" upper_limit="35.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 24 (n=140, 116, 81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.74" lower_limit="30.64" upper_limit="36.84"/>
                    <measurement group_id="O2" value="30.42" lower_limit="27.21" upper_limit="33.63"/>
                    <measurement group_id="O3" value="31.66" lower_limit="28.21" upper_limit="35.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 4, 8, 16, and 24 Weeks of the Self Esteem Domain of the Self-Esteem and Relationship (SEAR) Questionnaire</title>
        <description>SEAR assesses psychosocial outcomes in men with erectile dysfunction. The Self-Esteem domain consists of 4 items (items 9-12), each rated on a scale of 1 (Never) to 5 (Always). Item 11 is reverse scored (1=Always and 5=Never). The domain score was computed by summing its respective items, then transforming it into a 0 (least favorable) to 100 (most favorable) scale. The transformed score = 100 x [(actual raw score - lowest possible raw score)/possible raw score range]. Least Squares Mean changes were adjusted for baseline score, treatment group, country, visit, and visit*treatment.</description>
        <time_frame>Baseline, 4, 8, 16, and 24 weeks</time_frame>
        <population>The analysis included all randomly assigned participants who had a baseline and post-baseline SEAR Self-Esteem observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil On Demand</title>
            <description>Participants were instructed to take a 10-milligram (mg) or 20-mg tablet of tadalafil orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil Once a Day</title>
            <description>Participants were instructed to take a 5-mg or 2.5-mg tablet of tadalafil orally once a day for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Sildenafil Citrate On Demand</title>
            <description>Participants were instructed to take a 50-mg, 100-mg, or 25-mg tablet of sildenafil citrate orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 4, 8, 16, and 24 Weeks of the Self Esteem Domain of the Self-Esteem and Relationship (SEAR) Questionnaire</title>
          <description>SEAR assesses psychosocial outcomes in men with erectile dysfunction. The Self-Esteem domain consists of 4 items (items 9-12), each rated on a scale of 1 (Never) to 5 (Always). Item 11 is reverse scored (1=Always and 5=Never). The domain score was computed by summing its respective items, then transforming it into a 0 (least favorable) to 100 (most favorable) scale. The transformed score = 100 x [(actual raw score - lowest possible raw score)/possible raw score range]. Least Squares Mean changes were adjusted for baseline score, treatment group, country, visit, and visit*treatment.</description>
          <population>The analysis included all randomly assigned participants who had a baseline and post-baseline SEAR Self-Esteem observation.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="251"/>
                <count group_id="O3" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to 4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.18" lower_limit="21.95" upper_limit="28.41"/>
                    <measurement group_id="O2" value="24.10" lower_limit="20.90" upper_limit="27.30"/>
                    <measurement group_id="O3" value="26.59" lower_limit="23.39" upper_limit="29.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to 8 Weeks (n=230, 233, 233)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.14" lower_limit="25.93" upper_limit="32.35"/>
                    <measurement group_id="O2" value="27.80" lower_limit="24.60" upper_limit="30.99"/>
                    <measurement group_id="O3" value="28.92" lower_limit="25.75" upper_limit="32.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to 16 Weeks (n=167, 147, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.23" lower_limit="32.20" upper_limit="38.26"/>
                    <measurement group_id="O2" value="29.46" lower_limit="26.37" upper_limit="32.55"/>
                    <measurement group_id="O3" value="33.85" lower_limit="30.50" upper_limit="37.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to 24 Weeks (n=140, 116, 81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.86" lower_limit="32.59" upper_limit="39.12"/>
                    <measurement group_id="O2" value="31.14" lower_limit="27.75" upper_limit="34.52"/>
                    <measurement group_id="O3" value="33.52" lower_limit="29.88" upper_limit="37.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 4, 8, 16, and 24 Weeks of the Overall Relationship Domain of the Self-Esteem and Relationship (SEAR) Questionnaire</title>
        <description>SEAR assesses psychosocial outcomes in men with erectile dysfunction. The Overall Relationship domain consists of 2 items (items 13-14), each rated on a scale of 1 (Never) to 5 (Always). The domain score was computed by summing its respective items, then transforming it into a 0 (least favorable) to 100 (most favorable) scale. The transformed score = 100 x [(actual raw score - lowest possible raw score)/possible raw score range]. Least Squares Mean changes were adjusted for baseline score, treatment group, country, visit, and visit*treatment.</description>
        <time_frame>Baseline, 4, 8, 16, and 24 weeks</time_frame>
        <population>The analysis included all randomly assigned participants who had a baseline and post-baseline SEAR Overall Relationship observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil On Demand</title>
            <description>Participants were instructed to take a 10-milligram (mg) or 20-mg tablet of tadalafil orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil Once a Day</title>
            <description>Participants were instructed to take a 5-mg or 2.5-mg tablet of tadalafil orally once a day for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Sildenafil Citrate On Demand</title>
            <description>Participants were instructed to take a 50-mg, 100-mg, or 25-mg tablet of sildenafil citrate orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 4, 8, 16, and 24 Weeks of the Overall Relationship Domain of the Self-Esteem and Relationship (SEAR) Questionnaire</title>
          <description>SEAR assesses psychosocial outcomes in men with erectile dysfunction. The Overall Relationship domain consists of 2 items (items 13-14), each rated on a scale of 1 (Never) to 5 (Always). The domain score was computed by summing its respective items, then transforming it into a 0 (least favorable) to 100 (most favorable) scale. The transformed score = 100 x [(actual raw score - lowest possible raw score)/possible raw score range]. Least Squares Mean changes were adjusted for baseline score, treatment group, country, visit, and visit*treatment.</description>
          <population>The analysis included all randomly assigned participants who had a baseline and post-baseline SEAR Overall Relationship observation.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="251"/>
                <count group_id="O3" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.92" lower_limit="16.41" upper_limit="23.44"/>
                    <measurement group_id="O2" value="21.10" lower_limit="17.63" upper_limit="24.57"/>
                    <measurement group_id="O3" value="22.00" lower_limit="18.52" upper_limit="25.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 8 (n=229, 232, 232)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.75" lower_limit="19.19" upper_limit="26.31"/>
                    <measurement group_id="O2" value="22.96" lower_limit="19.43" upper_limit="26.50"/>
                    <measurement group_id="O3" value="23.74" lower_limit="20.22" upper_limit="27.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 16 (n=166, 147, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.63" lower_limit="26.46" upper_limit="32.79"/>
                    <measurement group_id="O2" value="26.96" lower_limit="23.74" upper_limit="30.17"/>
                    <measurement group_id="O3" value="28.57" lower_limit="25.07" upper_limit="32.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 24 (n=139, 116, 81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.28" lower_limit="26.93" upper_limit="33.62"/>
                    <measurement group_id="O2" value="29.93" lower_limit="26.43" upper_limit="33.43"/>
                    <measurement group_id="O3" value="28.74" lower_limit="24.93" upper_limit="32.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Tadalafil On Demand</title>
          <description>Participants were instructed to take a 10-milligram (mg) or 20-mg tablet of tadalafil orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Tadalafil Once a Day</title>
          <description>Participants were instructed to take a 5-mg or 2.5-mg tablet of tadalafil orally once a day for 24 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Sildenafil Citrate On Demand</title>
          <description>Participants were instructed to take a 50-mg, 100-mg, or 25-mg tablet of sildenafil citrate orally on demand, with a maximum of 4 tablets per week (and no more than 1 tablet per day) for 24 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital, familial and genetic disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Pulmonary sequestration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Hepatobiliary disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Oesophageal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Spinal laminectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Surgical and medical procedures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Venous insufficiency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="103" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="52" subjects_affected="21" subjects_at_risk="250"/>
                <counts group_id="E2" events="79" subjects_affected="30" subjects_at_risk="257"/>
                <counts group_id="E3" events="32" subjects_affected="10" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" events="27" subjects_affected="17" subjects_at_risk="250"/>
                <counts group_id="E2" events="22" subjects_affected="10" subjects_at_risk="257"/>
                <counts group_id="E3" events="17" subjects_affected="10" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" events="117" subjects_affected="44" subjects_at_risk="250"/>
                <counts group_id="E2" events="51" subjects_affected="19" subjects_at_risk="257"/>
                <counts group_id="E3" events="110" subjects_affected="40" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="40" subjects_affected="16" subjects_at_risk="250"/>
                <counts group_id="E2" events="12" subjects_affected="5" subjects_at_risk="257"/>
                <counts group_id="E3" events="26" subjects_affected="8" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="56" subjects_affected="21" subjects_at_risk="250"/>
                <counts group_id="E2" events="24" subjects_affected="8" subjects_at_risk="257"/>
                <counts group_id="E3" events="63" subjects_affected="23" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" events="45" subjects_affected="16" subjects_at_risk="250"/>
                <counts group_id="E2" events="33" subjects_affected="17" subjects_at_risk="257"/>
                <counts group_id="E3" events="20" subjects_affected="9" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="30" subjects_affected="10" subjects_at_risk="250"/>
                <counts group_id="E2" events="32" subjects_affected="14" subjects_at_risk="257"/>
                <counts group_id="E3" events="49" subjects_affected="23" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" events="36" subjects_affected="14" subjects_at_risk="250"/>
                <counts group_id="E2" events="41" subjects_affected="19" subjects_at_risk="257"/>
                <counts group_id="E3" events="60" subjects_affected="27" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" events="37" subjects_affected="11" subjects_at_risk="250"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="257"/>
                <counts group_id="E3" events="46" subjects_affected="17" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

